Tysabri (natalizumab) is not classified as an immunosuppressant. The FDA categorizes it as an immunomodulator, meaning it changes how the immune system behaves rather than broadly weakening it. This distinction matters because Tysabri works in a very targeted way: it blocks immune cells from crossing into the brain and spinal cord, rather than reducing the body’s overall ability to fight infection. That said, this targeted action still carries real infection risks that overlap with what you’d expect from immunosuppressive drugs.
Why the Classification Matters
Traditional immunosuppressants work by reducing the number or activity of immune cells throughout the body. Tysabri does something different. It acts as a gatekeeper, preventing certain white blood cells from leaving the bloodstream and entering the central nervous system. Your immune cell counts in the blood don’t drop on Tysabri. In fact, they go up. Studies of patients on natalizumab show that total white blood cell counts, lymphocyte counts, and a type of immune cell called eosinophils all increase significantly within the first month of treatment and stay elevated. Monocyte counts rise progressively over 18 months of treatment.
So your blood has more immune cells circulating, not fewer. The issue is that those cells can’t get where they normally would, which leaves certain tissues, particularly the brain, with reduced immune surveillance.
How Tysabri Works
Tysabri is a lab-made antibody that latches onto a specific protein on the surface of immune cells called alpha-4 integrin. Normally, this protein acts like a key that lets immune cells grab onto blood vessel walls and squeeze through into surrounding tissue. By blocking that key, Tysabri prevents immune cells from crossing the blood-brain barrier into the brain and spinal cord.
In multiple sclerosis, immune cells that cross into the brain mistakenly attack the protective coating around nerve fibers. Tysabri stops this attack at the doorway. The same mechanism is useful in Crohn’s disease, where the drug blocks immune cells from flooding into inflamed gut tissue. It’s approved for both conditions, given as a 300 mg intravenous infusion once every four weeks.
Infection Risks That Blur the Line
Even though Tysabri doesn’t suppress the immune system body-wide, it creates a vulnerability that looks a lot like immunosuppression in practice. The most serious risk is progressive multifocal leukoencephalopathy (PML), a rare brain infection caused by the JC virus. PML typically only occurs in people who are immunocompromised, and its association with Tysabri is the main reason the drug carries a black box warning. PML usually leads to severe disability or death.
Tysabri also increases the risk of herpes-related infections in the brain and eyes. Serious and sometimes fatal cases of herpes encephalitis and meningitis have been reported. A related condition called acute retinal necrosis, a rapid viral infection of the retina caused by herpes viruses, occurs at higher rates in Tysabri-treated patients and has led to blindness in some cases.
Beyond these, clinical studies have documented opportunistic infections in less than 1% of patients, including fungal lung infections, a type of bacterial infection involving mycobacterium, and cryptococcal meningitis. One patient developed a prolonged cryptosporidial gut infection. More common, less severe infections also increase on treatment: pneumonias, urinary tract infections, stomach bugs, vaginal infections, tooth infections, tonsillitis, and herpes flare-ups all occurred more frequently in treated patients than in those receiving a placebo.
PML Risk Factors and Monitoring
Not everyone on Tysabri faces the same level of PML risk. Three factors drive it: whether you carry antibodies against the JC virus, how long you’ve been on the drug, and whether you’ve previously taken immunosuppressant medications. Doctors use a blood test called the JC virus antibody index to quantify your risk more precisely.
The numbers vary enormously depending on your profile. Patients under 45 at the start of treatment with a low JC virus antibody index (below 0.9) and certain favorable immune markers face a risk as low as less than 1 in 10,000. On the other end, patients with a high antibody index, longer treatment duration, and unfavorable markers can face a risk as high as 1 in 33. An antibody index above 0.9 is the threshold where PML probability starts climbing more steeply, particularly after two or more years of treatment.
Even a negative JC virus antibody test doesn’t eliminate the risk entirely, because you could acquire the virus later or the test could return a false negative. Periodic retesting is standard.
The TOUCH Prescribing Program
Because of the PML risk, Tysabri is only available through a restricted program called TOUCH. You can’t simply pick it up at a pharmacy. Both you and your prescribing doctor must be enrolled, and infusions happen at authorized centers staffed by nurses trained on the drug’s risks. Before each infusion, you’ll be asked about any new or worsening symptoms, infections, other medications, and changes to your health.
Your doctor will test for JC virus antibodies before starting treatment and periodically afterward. For six months after your last infusion, you still need to watch for and immediately report new neurological symptoms: changes in thinking, vision, balance, strength, or weakness on one side of the body lasting more than a few days. PML risk doesn’t disappear the moment you stop treatment.
Immunomodulator vs. Immunosuppressant in Practice
The technical classification of Tysabri as an immunomodulator is accurate. It reshapes immune behavior rather than suppressing immune cell production or function across the board. But the practical reality is more nuanced. By blocking immune cells from reaching the brain, Tysabri creates localized immune blind spots that allow viruses like JC and herpes to reactivate. The types of infections it enables, particularly PML, are hallmarks of immunocompromised states.
If you’re asking this question because you’re weighing treatment options, the useful takeaway is that Tysabri doesn’t weaken your immune system the way chemotherapy or organ transplant drugs do. Your everyday ability to fight colds, heal wounds, and respond to vaccines remains largely intact. The risk is narrower but concentrated in a dangerous area: the brain. That tradeoff, combined with the JC virus antibody testing that can quantify your personal risk, is what makes the treatment decision so individual.